SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is facing significant market pressure following a reported security vulnerability in its VMware software and analyst concerns regarding the company's AI financing exposure. The community remains deeply divided, with some investors liquidating positions due to the negative news cycle, while others view the pullback as a buying opportunity given the firm's long-term strength in the semiconductor and AI infrastructure sectors.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as retail investors rally behind a fundamental breakout, fueled by a landmark cross-licensing agreement with Samsung and new patent infringement complaints against Micron and other tech giants. The community is actively debating the stock's long-term potential, citing looming legal catalysts, significant short interest, and the company's strengthening position within the AI-driven memory market.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending as investors monitor anticipation surrounding upcoming second-quarter earnings, with the community closely tracking potential catalysts like revenue growth and the impact of heavy short interest on price volatility. Discussions are centered on the company's progress in AI infrastructure and the belief that the stock is currently oversold, leaving many traders actively searching for an official earnings date to gauge the next move.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is trending as the ETF hits all-time highs, driven by investor optimism despite rising yields and geopolitical tensions in the Middle East. The community is actively debating the sustainability of this rally, with some traders highlighting the potential for volatility and rotation while others look for opportunities in the ongoing small-cap strength.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is experiencing significant upward momentum following an earnings report that signaled robust revenue growth and strong institutional accumulation, with over 80% of shares now held by institutional investors. The community is actively discussing the stock's potential for a short squeeze and long-term valuation gains, driven by the upcoming NSCLC clinical data and the company's expanding commercial infrastructure.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense community debate following its price dip below the one-dollar mark, a level many investors previously viewed as a critical support floor. Discussions are polarized between investors viewing the decline as a strategic buying opportunity driven by institutional accumulation and others expressing frustration over regulatory delays and perceived lack of utility.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is gaining significant attention as investors react to the administration's imposition of 100% tariffs on imported drones, a policy catalyst aimed at bolstering the domestic manufacturing sector. The community is actively debating the stock's potential for a major short squeeze, given its high short interest and limited public float, while weighing the long-term impact of potential government contracts against concerns over share dilution and speculative trading activity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following a strong quarterly performance where the company exceeded revenue expectations, raised full-year EBITDA guidance, and confirmed a new supply agreement with a major dialysis provider. Investors are actively debating the company's long-term commercial outlook, specifically focusing on the sustainability of DefenCath revenue and the potential for a share price re-rating as the company navigates the post-TDAPA reimbursement environment.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

Boost Run is capturing market interest following a strong earnings report that highlighted significant revenue growth and major new GPU infrastructure contracts. While the community is actively debating the impact of a recent warrant redemption and lock-up period on the share price, many investors are focused on the company's long-term growth potential and its status as an NVIDIA preferred cloud partner.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors react to positive Phase III HARMONi-6 trial data, which demonstrated a statistically significant overall survival benefit for ivonescimab compared to standard therapy. The community is actively debating the significance of these results, with bulls emphasizing the potential to unseat current standard-of-care blockbusters, while some skeptics focus on the trial's reliance on Chinese data and the need for global validation ahead of upcoming regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus 

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Key PointsCathie Wood continues adding shares of Beam Therapeutics...

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.read more...

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

Equity

An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam Therapeutics. 


BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria

Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.

Beam Therapeutics Stock Soars 21% in Three Months: Here's Why

BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$26.74
Prev Close	$26.51
Open	$26.71
Dividend Yield	0.00%
50-Day Moving Average	$30.18
Beta	1.92
Avg. Volume	2.35M
PE Ratio	-30.82

52-Week High	$38.26
52-Week Low	$15.60
Market Capitalization	$2.74B
EPS (Annual)	-$0.8088
Price to Book	2.56
Revenue Per Employee	$273,469.67

Feed

News

Sentiment

Earnings

Fundamentals

Info